Evidence map›Paper›PMID 39824992›Full record

ArticleMedical oncology (Northwood, London, England)2025

Protocatechuic aldehyde sensitizes BRAF-mutant melanoma cells to temozolomide through inducing FANCD2 degradation.

Jie Yang, Xin Zeng, Junxia Pei, Zhou Su, Qi Liu, Yamei Zhang, Yixi Yang, Rui Li, Fei Zhou, Yu Deng

Abstract read
PubMed Publisher
In one paragraph

Article in Medical oncology (Northwood, London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jie YangEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Xin ZengEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Junxia PeiEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Zhou SuEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Qi LiuEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Yamei ZhangKey Laboratory of Clinical Genetics, Affiliated Hospital of Chengdu University, Chengdu, 610106, China.
Yixi YangEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Rui LiEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China.
Fei ZhouDepartment of Oncology, Shanghai General Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, 200080, China. zhoufei.2013@hotmail.com.
Yu DengEngineering Research Center of Sichuan-Tibet Traditional Medicinal Plant, Chengdu University, Chengdu, 610106, China. dengyu@cdu.edu.cn.

Funding

Innovation Foundation of The Affiliated Hospital of Chengdu University Grant No. CDFYCX202209Major Research and Development Plan of Tibet Autonomous Region Grant No. XZ202201ZY0031GNational Natural Science Foundation of China Grant No. 82174202Natural Science Foundation of Sichuan Province Grant No.2022NSFSC0726
6 · The paper itself

Abstract

Temozolomide (TMZ)-based chemotherapy is a primary regimen for melanoma patients who have failed targeted therapy or immunotherapy. However, the low response rate of TMZ-based chemotherapy challenges the patients' prognosis. BRAF

Indexed as

BenzaldehydesFanconi Anemia Complementation Group D2 ProteinMelanomaProto-Oncogene Proteins B-rafTemozolomideAntineoplastic Agents, AlkylatingApoptosisCatecholsCell Line, TumorDrug Resistance, NeoplasmDrug SynergismHumansMutationAntineoplastic Agents, AlkylatingBenzaldehydesBRAF protein, humanCatecholsFANCD2 protein, humanFanconi Anemia Complementation Group D2 ProteinprotocatechualdehydeProto-Oncogene Proteins B-rafTemozolomideFANCD2MelanomaProtocatechuic aldehydeSynergyTemozolomide

Identifiers

PMID39824992

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.